The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending that patients being treated for visual impairment caused by chronic diabetic macular oedema ...

Incorporation of an artificial intelligence-based-optical coherence tomography (AI-OCT) system as a secondary screening tool is noninferior to standard practice and can reduce unnecessary diabetic ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

Please provide your email address to receive an email when new articles are posted on . Knowledge gaps and controversies remain a barrier to understanding the relevance of OCT biomarkers as predictors ...

Exonate Ltd. (the Company), an mRNA therapy company focused on treatments for diabetic complications, today announced its lead ophthalmology asset, EXN407, has achieved its prespecified endpoints in a ...

Vision tools, rehabilitation, and lifestyle changes can all help improve the experience of living with diabetic macular edema (DME). Macular edema is a condition that involves swelling in the eye that ...

CAMBRIDGE, England & NOTTINGHAM, England--(BUSINESS WIRE)--Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases ...

What Is Eylea HD, and Why Does It Matter? Eylea HD (aflibercept) is an injectable medicine used to treat certain eye conditions that can lead to vision loss. It works by blocking a protein called VEGF ...

4D Molecular Therapeutics (4DMT) has received regenerative medicine advanced therapy (RMAT) designation from the US Food and Drug Administration (FDA) for 4D-150 for diabetic macular oedema. The ...

Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced the data from a successful Phase Ib/IIa ...